Results 291 to 300 of about 198,039 (308)

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Nature Medicine, 2023
Farshad Nassiri, Olivia Singh, Timothy Cloughesy   +2 more
exaly  

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Taofeek Kunle Owonikoko, Nabil F Saba   +2 more
exaly  

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Nature Medicine, 2020
Bruno Bockorny, Teresa Macarulla, Erkut Borazanci   +2 more
exaly  

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Lancet, The, 2021
Jong-Mu Sun, Manish A Shah, Toshihiko Doi   +2 more
exaly  

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Journal of Clinical Oncology, 2020
Aurelien Marabelle, Dung T Le, Paolo A Ascierto   +2 more
exaly  

Current recommendations and recent progress in endometrial cancer

Ca-A Cancer Journal for Clinicians, 2019
Gini F Fleming
exaly  

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Journal of Clinical Oncology, 2020
, Baek-Yeol Ryoo, Philippe Merle
exaly  

Hodgkin lymphoma: A review and update on recent progress

Ca-A Cancer Journal for Clinicians, 2018
Satish P Shanbhag, Richard F Ambinder
exaly  

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Lancet, The, 2020
Javier Cortes, David W Cescon, Hope S Rugo   +2 more
exaly  

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Lancet, The, 2019
Yi-Long Wu, Dariusz M Kowalski, Byoung Chul Cho   +2 more
exaly